Tadalafil Administered Once Daily for Treatment of Lower Urinary Tract Symptoms in Korean men with Benign Prostatic Hyperplasia: Results from a Placebo-Controlled Pilot Study Using Tamsulosin as an Active Control

LUTS: Lower Urinary Tract Symptoms

Volumn 3, Issue 2, 2011, Pages 86-93

  Kim, Sae Chul ^a   Park, Jong Kwan ^b   Kim, Sae Woong ^c   Lee, Sung Won ^d   Ahn, Tai Young ^e   Kim, Je Jong ^f   Paick, Jae Seung ^g   Park, Nam Cheol ^h   Park, Kwangsung ⁱ   Min, Kweon Sik ^j   Kraus, Stephen R ^k   Secrest, Roberta J ^l   Elion Mboussa, Albert ^l   Viktrup, Lars ^l  

^a Chung Ang University College of Medicine   (South Korea)

^b Chonbuk National University Medical School   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Asan Medical Center   (South Korea)

^f Korea University Ansan Hospital   (South Korea)

^g Seoul National University Hospital   (South Korea)

^h Pusan National University Hospital   (South Korea)

ⁱ Chonnam National University   (South Korea)

^j Inje University College of Medicine   (South Korea)

^k Mays Cancer Center at UT Health San Antonio   (United States)

^l ELI LILLY AND COMPANY   (United States)

more..

Author keywords

Benign prostatic hyperplasia; International Prostate Symptom Score; Lower urinary tract symptoms; Tadalafil; Tamsulosin

Indexed keywords

PLACEBO; TADALAFIL; TAMSULOSIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPIGASTRIC DISCOMFORT; FLUSHING; GASTRIC ULCER BLEEDING; HEADACHE; HUMAN; HYPERLIPIDEMIA; INGUINAL HERNIA; INSOMNIA; INTERNATIONAL PROSTATE SYMPTOM SCORE; KOREA; LACERATION; LOWER URINARY TRACT SYMPTOM; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; MULTICENTER STUDY; MUSCULOSKELETAL CHEST PAIN; MYALGIA; PILOT STUDY; PLEURA EFFUSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SPINE DISEASE; STENOSIS; THORAX PAIN; URINE FLOW RATE;

EID: 80052582353     PISSN: 17575664     EISSN: 17575672     Source Type: Journal    
DOI: 10.1111/j.1757-5672.2011.00088.x     Document Type: Article

References (19)

1. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-49.
2. Homma Y, Kawabe K, Tsukamoto T et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol 1997; 4: 40-6.
3. Chung TG, Chung J, Lee B, Kim HH. Prevalence of benign prostatic hyperplasia in Jeong-Eup area: community-based study. Korean J Urol 1999; 40: 52-8.
4. Hong J, Kwon S, Yoon H et al. Risk factors for benign prostatic hyperplasia in South Korean men. Urol Int 2006; 76: 11-9.
5. American Urological Association (AUA). Benign Prostatic Hyperplasia (BPH) Guideline Update Panel: Guideline Management of Benign Prostastic Hyperplasia (BPH). [Revised 2010.] Available from URL:.
6. Lee ES, Lee C. Effect of tamsulosin, a selective alpha1A-andrenoreceptor antagonist, in benign prostatic hyperplasia. Korean J Urol 1997; 38: 158-66.
7. Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H, YM617 Clinical Study Group. Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 1990; 144: 908-11.
8. Filippi S, Morelli A, Sandner P et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-29.
9. Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484-90.
10. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228-34.
11. Boehringer Ingelheim. Flomax Prescribing Information. 2009.
12. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003; 189: 98-101.
13. Yalcin I, Viktrup L. Comparison of physician and patient assessments of incontinence severity and improvement. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18: 1291-5.
14. Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770-4.
15. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401-7.
16. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006; 98: 1019-24.
17. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177: 1071-7.
18. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236-44.
19. Roehrborn CG. Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. Rev Urol 2004; 6: 121-7.